Cite
MLA Citation
L. Zuo et al.. “106P Zanubrutinib in combination with tislelizumab in patients with refractory diffuse large B cell lymphoma (DLBCL): A phase II study.” Immuno-oncology technology, vol. 16, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100172069869.0x000007